Skip to main content
Premium Trial:

Request an Annual Quote

How Many and For How Long?

Researchers are hoping to develop a blood test to gauge whether SARS-CoV-2 vaccines are effective as well as how long their protection may last, NPR reports. It adds that such a test may be needed if new or updated vaccines are necessary to combat viral variants.

According to NPR, researchers at the University of Oxford are exposing people who previously had COVID-19 to the virus to learn what level of antibodies are needed to fight off infection. Knowing that cut-off titer could help determine how long vaccine-induced protection lasts, it says.

At the same time, researchers at Fred Hutchinson Cancer Research Center are analyzing blood samples from people taken the day they received the Moderna vaccine as well as the day they received their second dose and a few weeks after that. This analysis, too, could give insight into antibody levels needed to prevent infection, particularly if any of the 1,600 people in the study later develop COVID-19.

"Everyone in the field is waiting for those results to give more confidence in being able to approve other vaccines more quickly and more reliably. So, we're getting close. We're almost there, actually," the Fred Hutch's Peter Gilbert says.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.